Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
Chiara De PhilippisCristina ZucchinettiDaniele ManninaMauro KramperaPier Luigi Luigi ZinzaniAnnalisa ChiappellaAlice di RoccoEnrico OrciouloMaria Chiara TisiFlavio PistoleseLaura GiordanoArmando SantoroStefania BramantiPublished in: Bone marrow transplantation (2024)